Skleo CEO Discusses Legal Impact of dm Screening Case and Optical Partner Strategy

In an interview with FOCUS Augenoptik, Skleo Health CEO Dr. Alex Hein addressed the pending court ruling regarding eye screenings offered at drugstore chain dm. The Landgericht Karlsruhe is expected to deliver its verdict in late November 2026. Hein stated that while legal clarity is necessary for modern preventive care, Skleo’s operations continue as planned. He highlighted that over 70% of Skleo users had not visited an ophthalmologist in more than two years. Regarding retail partnerships, Hein noted that most Skleo locations are within optical shops. He described a "drive-to-store" concept where customers identified by dm screenings needing correction are referred to partner opticians. Additionally, since September, health insurer mkk has covered costs for Skleo screenings targeting individuals with Type-2 diabetes, with further negotiations ongoing.